



WEST VIRGINIA MEDICAID PHARMACY DEPARTMENT

<http://www.dhhr.wv.gov/bms/Pharmacy>

PROVIDER SERVICES

888-483-0793

888-483-0801 (Pharmacy)

304-348-3360

Monday – Friday

8:00 am until 5:00 pm

PHARMACY HELP DESK & PHARMACY PRIOR AUTHORIZATION (RATIONAL DRUG THERAPY PROGRAM)

800-847-3859 (Phone)

800-531-7787 (Fax)

Monday – Saturday

8:30 am until 9:00 pm

Sunday 12:00 pm until 6:00 pm

MEMBER SERVICES

888-483-0797

304-348-3365

Monday – Friday

8:00 am until 5:00 pm

PREFERRED DRUG LIST

For a copy of the most recent preferred drug list, visit:

<http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pdl.aspx>

STATE MAXIMUM ALLOWABLE COST (SMAC)

SMAC Review Form:

<http://www.dhhr.wv.gov/bms/Pharmacy/Pages/smac.aspx>

Please refer questions to Magellan at 1-800-763-7382 or e-mail to

StateSMACProgram@magellanhealth.com

Prescribing of Naloxone for Opioid Overdoses

Opioid prescribing doubled between the 1990s and 2012 when pain became the subject of quality initiatives and practice guidelines.^{1,2} More Americans now die every year from drug overdoses than they do in motor vehicle crashes.³ Clinically, the risk for overdose is directly associated with the use of multiple prescribers and daily dosages of greater than 100 morphine milligram equivalents (MMEs) per day.⁴ PrescribeToPrevent.Org was developed by advocates to assist providers who want to make naloxone available to their patients, but are unsure how to do it.⁵

Naloxone can be prescribed as generic naloxone vials for intramuscular injection, as prefilled syringes for intranasal use, or as branded Evzio™ autoinjectors.

- Generic naloxone 0.4 mg/mL, single-dose vials should be prescribed in pairs (dispense two 1 mL single-dose vials) or one 10 mL multi-dose vial. Needles (23 gauge, 1 inch) and syringes (3 cc) must also be prescribed.
- Intranasal naloxone should be prescribed as naloxone 2 mg/2 mL prefilled syringes along with two nasal atomizer devices to fit the prefilled syringes.
- Each Evzio carton contains two auto-injectors, each containing naloxone 0.4 mg, and one trainer.

PrescribeToPrevent.Org developed one page physician prescribing instructions for each generic naloxone product complete with basic information about patient assessment, calling for help, drug administration, and poison control contact instructions. The Evzio prescribing instructions are branded from the manufacturer. In addition to prescribing instructions and patient information, the website can help providers select candidates for treatment and bill for the clinical encounter to prescribe naloxone.

Pharmacist assistance is well represented at PrescribeToPrevent.Org. It is “strongly recommend that prescribers and pharmacists coordinate the logistics of prescription writing, assembling rescue kit components, and understand billing options prior to sending patients to have their prescriptions filled.” Collaboration between providers will ensure patients fill prescriptions successfully and know what payment is expected.

The President of the United States recently visited West Virginia and discussed a Memorandum to Federal Departments and Agencies regarding the heroin epidemic and prescription drug abuse.³ The memo stresses the importance of prescriber training and improving access to drug abuse treatment. Consider incorporating the tools available at PrescribeToPrevent.org into your practice. The West Virginia Medicaid Preferred Drug List covers generic naloxone 0.4 mg/mL vials and intranasal naloxone 2 mg/2 mL prefilled syringes without prior authorization or quantity restriction.

References:

1. National Pharmaceutical Council, Inc. Pain: current understanding of assessment, management, and treatments. December 2001. <http://www.npcnow.org/publication/pain-current-understanding-assessment-management-and-treatments>. (Accessed November 4, 2015).
2. CDC. Prescription drug abuse and overdose: public health perspective. October 24, 2012. <http://www.cdc.gov/primarycare/materials/opioidabuse/docs/pda-pherspective-508.pdf> (Accessed November 4, 2015).
3. The White House, Office of the Press Secretary (2015, October 21). Fact Sheet: Obama Administration Announces Public and Private Sector Efforts to Address Prescription Drug Abuse and Heroin Use. <https://www.whitehouse.gov/the-press-office/2015/10/21/fact-sheet-obama-administration-announces-public-and-private-sector> (Accessed November 4, 2015).
4. Centers for Disease Control and Prevention (CDC). (2015, October 16). Controlled Substance Prescribing Patterns — Prescription Behavior Surveillance System, Eight States, 2013. MMWR. Morbidity and Mortality Weekly Reports. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6409a1.htm?s_cid=ss6409a1_e (Accessed November 4, 2015).
5. Welcome to Prescribe To Prevent. Prescribe to Prevent. <http://prescribetoprevent.org> (Accessed November 4, 2015).

Upcoming PDL Changes

The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2016.

NOTE: For changes in red italics existing users will be grandfathered though December 31, 2015. For changes in red italics existing users will be grandfathered though December 31, 2015 when used for migraine prophylaxis.

For a comprehensive PDL, refer to <http://www.dhhr.wv.gov/bms/Pharmacy/ptc/Pages/default.aspx>.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED FOR PREFERRED STATUS
ANALGESICS, NARCOTIC LONG ACTING (NON-PARENTERAL)	BUTRANS (buprenorphine)
ANALGESICS, NARCOTIC LONG ACTING (NON-PARENTERAL)	NUCYNTA ER (tapentadol)
ANALGESICS, NARCOTIC SHORT ACTING (NON-PARENTERAL)	NUCYNTA (tapentadol)
ANALGESICS, NARCOTIC SHORT ACTING (NON-PARENTERAL)	oxycodone concentrate, solution
ANGIOTENSIN MODULATORS	TRIBENZOR (olmesartan/amlodipine/HCTZ)
ANGIOTENSIN MODULATORS	valsartan/amlodipine
ANTICONVULSANTS	DILANTIN (sodium, extended)
ANTICONVULSANTS	felbamate
ANTICONVULSANTS	FYCOMPA (perampanel)
ANTICONVULSANTS	levetiracetam ER
ANTICONVULSANTS	oxcarbazepine suspension
ANTICONVULSANTS	topiramate ER
ANTIPSYCHOTICS, ATYPICAL	clozapine ODT
ANTIPSYCHOTICS, ATYPICAL	INVEGA TRINZA (paliperidone)
ANTIPSYCHOTICS, ATYPICAL	olanzapine ODT
CYTOKINE & CAM ANTAGONISTS	COSENTYX (secukinumab)
GLUCOCORTICOIDS, INHALED	BREO ELLIPTA (fluticasone/vilanterol)
GROWTH HORMONE	NUTROPIN AQ (somatropin)
HEPATITIS C TREATMENTS	SOVALDI (sofosbuvir)
HEPATITIS C TREATMENTS	TECHNIVIE (ombitasvir/paritaprevir/ritonavir)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	BYDUREON (exanatide microspheres)
IMMUNE GLOBULINS, IV	GAMMAKED (human immunoglobulin gamma)
IMMUNE GLOBULINS, IV	OCTAGAM (human immunoglobulin gamma)
IMMUNE GLOBULINS, IV	PRIVIGEN (human immunoglobulin gamma)
INTRANASAL RHINITIS AGENTS	QNASL HFA (beclomethasone)
LIPOTROPICS, OTHER (NON-STATINS)	fenofibrate 150mg
LIPOTROPICS, OTHER (NON-STATINS)	fenofibrate nanocrystallized 48mg, 145mg
MULTIPLE SCLEROSIS AGENTS	BETASERON (interferon beta-1b)
MULTIPLE SCLEROSIS AGENTS	GILENYA (fingolimod)
OPHTHALMIC ANTIBIOTICS	BESIVANCE (besifloxacin)
OPHTHALMIC ANTIBIOTICS	neomycin/polymyxin/gramicidin
OPHTHALMIC ANTIBIOTICS/STEROID COMBINATIONS	TOBRADEX ST (tobramycin/ dexamethasone)
OPHTHALMICS, GLAUCOMA AGENTS	ALPHAGAN P 0.15% Solution (brimonidine)
OTIC ANTIBIOTICS	CIPRO HC (ciprofloxacin/hydrocortisone)
OTIC ANTIBIOTICS	ciprofloxacin
STIMULANTS AND RELATED AGENTS	DEXEDRINE ER (dextroamphetamine)
STIMULANTS AND RELATED AGENTS	dexmethylphenidate IR
STIMULANTS AND RELATED AGENTS	dextroamphetamine IR
STIMULANTS AND RELATED AGENTS	METHYLIN SOLUTION (methylphenidate)
STIMULANTS AND RELATED AGENTS	methylphenidate ER (authorized generic Concerta – Actavis labeler 00591)
STIMULANTS AND RELATED AGENTS	methylphenidate IR

Upcoming PDL Changes, Continued

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED FOR NON-PREFERRED STATUS
ALZHEIMER'S AGENTS	NAMZARIC(donepezil/memantine)
ANALGESICS, NARCOTIC LONG ACTING (NON-PARENTERAL)	fentanyl transdermal 37.5, 62.5, 87.5 mcg/hr
ANALGESICS, NARCOTIC SHORT ACTING (NON-PARENTERAL)	oxycodone capsules
ANALGESICS, NARCOTIC SHORT ACTING (NON-PARENTERAL)	ROXICODONE (oxycodone)
ANDROGENIC AGENTS	NATESTO (testosterone)
ANDROGENIC AGENTS	TESTIM (testosterone)
ANGIOTENSIN MODULATORS	ENTRESTO (valsartan/sucubitril)
ANGIOTENSIN MODULATORS	EXFORGE (valsartan/amlodipine)
ANTICOAGULANTS	FRAGMIN (dalteparin)
ANTICONVULSANTS	FELBATOL (felbamate)
ANTICONVULSANTS	TRILEPTAL SUSPENSION (oxcarbazepine)
ANTIFUNGALS, ORAL	CRESEMBA (isovuconazonium)
ANTIPSYCHOTICS, ATYPICAL	REXULTI (brexipiprazole)
ANTIPSYCHOTICS, ATYPICAL	SAPHRIS (asenapine)
COPD AGENTS	STIOLTO RESPIMAT (tiotropium/olodaterol)
BETA BLOCKERS	propranolol ER*
BLADDER RELAXANT PREPARATIONS	TOVIAZ (fesoterodine)
BRONCHODILATORS, BETA AGONIST	PROAIR RESPICLICK (albuterol)
GLUCOCORTICOIDS, INHALED	ADVAIR DISKUS (fluticasone/salmeterol)
HEPATITIS C TREATMENTS	DAKLINZA (daclatasvir)
HEPATITIS C TREATMENTS	MODERIBA 400 mg, 600 mg
HEPATITIS C TREATMENTS	MODERIBA DOSE PACK
HYPERPARATHYROID AGENTS	NATPARA (parathyroid hormone)
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	NOVOLIN (insulin)
INTRANASAL RHINITIS AGENTS	NASONEX (mometasone)
LIPOTROPICS, OTHER (NON-STATINS)	fenofibrate 120mg
LIPOTROPICS, OTHER (NON-STATINS)	PRALUENT (alirocumab)
MULTIPLE SCLEROSIS AGENTS	EXTAVIA KIT (interferon beta-1b)
MULTIPLE SCLEROSIS AGENTS	GLATOPA (glatiramer)
NEUROPATHIC PAIN	IRENKA (duloxetine)
OPHTHALMIC ANTIBIOTICS/STEROID COMBINATIONS	BLEPHAMIDE S.O.P. (prednisolone/ sulfacetamide)
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ALREX (loteprednol)
OPHTHALMICS, GLAUCOMA AGENTS	ALPHAGAN P 0.15% SOLUTION (brimonidine)
OTIC ANTIBIOTICS	ofloxacin
STIMULANTS AND RELATED AGENTS	APTENSIO XR (methylphenidate)
STIMULANTS AND RELATED AGENTS	EVEKEO (amphetamine)
STIMULANTS AND RELATED AGENTS	FOCALIN IR (dexmethylphenidate)
STIMULANTS AND RELATED AGENTS	methylphenidate chewable tablets
STIMULANTS AND RELATED AGENTS	methylphenidate ER